About this blog

CRIT is no longer adding posts or updating the CRITical Thinking blog.

CRITical Thinking is a blog written by staff, directors, and friends of the Collaboration for Research Integrity and Transparency (CRIT), a joint program of Yale Law School, Yale School of Public Health, and Yale School of Medicine. CRIT's mission is to promote health by improving the integrity and transparency of biomedical and clinical research.

This blog is published by and reflects the personal views of the individual authors, in their individual capacities. It does not purport to represent Yale University's institutional views, if any. No representation is made about the accuracy of the information, which solely constitutes the authors’ personal views on issues discussed. The information contained in this blog is provided only as general information and personal opinions, and blog topics may be updated after being initially posted.

 

Tags

trial reporting
data sharing
YaleCRIT17
reproducibility
FDA
regulatory approval
patient advocacy
medical evidence
research integrity
Pharmaceutical Marketing
lifecycle evaluation
EMA
market exclusivity
payers
trials
transparency
CCI
right to try
meta-research

CRITical Thinking Blog

What Does a Pro-Patient, Pro-Public Health Regulatory Agency Look Like?

September 13, 2017
By Michael Carome

A pro-patient, pro-public health agenda for the regulation of medical products should, among other things: (a) ensure that these products are safe and effective for their intended uses; (b) maximize transparency regarding regulatory actions and the data used to support those actions; (c) spur the development of new treatments that truly meet the health needs of patients throughout the world; (d) minimize both industry bias in the development of medical products and industry influence on prescribing practices; and (e) ensure that medical products are affordable for all patients who need them and for society.

Read more

Federal “Right to Try” Legislation – perpetuating a misguided skepticism towards the FDA

September 8, 2017
By Jeanie Kim

The “right to try” (RTT) movement presents a narrative that pits patients against the FDA. Supporters of RTT, powered by the libertarian Goldwater Institute, have pushed for laws that let terminally ill patients bypass regulators to access unapproved treatments.

Read more

Patient Advocacy Must Be Rooted in Evidence and Science Literacy to Make a Real Difference

August 31, 2017
By Fran Visco

An informed patient advocacy perspective is vital to ensuring the integrity and transparency of the research enterprise.

Read more

Are Payers Willing to Engage in Evidence-based Coverage Decisions?

August 29, 2017
By Dan Ollendorf

In June 2017, Yale CRIT hosted an international conference titled “Ensuring Safety, Efficacy, and Access to Medical Products in the Age of Global Deregulation.” The following blogpost is the fourth installment of a blog series with commentaries from the conference participants.

Read more

Pages